Pfizer Inc (MIL:1PFE)
€ 24.625 -0.215 (-0.87%) Market Cap: 139.23 Bil Enterprise Value: 192.39 Bil PE Ratio: 35.39 PB Ratio: 1.61 GF Score: 64/100

Pfizer Inc To Discuss Data From An Ongoing Phase 1/2 Study Of mRNA-Based Vaccine Candidate Against SARS-CoV-2 Call Transcript

Jul 1, 2020 / 06:00 PM GMT


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PFE.N - Pfizer Inc
Pfizer Inc To Discuss Data From An Ongoing Phase 1/2 Study Of mRNA-Based Vaccine Candidate Against SARS-CoV-2 Call
Jul 01, 2020 / 06:00PM GMT

=====================
Conference Call Participants
=====================
* >>Charles Triano - Head of IR
* >>Mikael Dolsten - Unit President
* >>Vamil Divan - Mizuho Securities USA LLC, Research Division
* >>Kathrin Jansen - Senior Key Executive
* >>Louise Chen - Cantor Fitzgerald & Co., Research Division
* >>Scott Puckhaber - BofA Merrill Lynch, Research Division
* >>David Risinger - Morgan Stanley, Research Division
* >>Seamus Fernandez - Guggenheim Securities, LLC, Research Division

=====================
Presentation
--------------------------------------------------------------------------------
Operator [1]
--------------------------------------------------------------------------------

Good day, everyone, and welcome to Pfizer's Analyst and
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot